Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.
Dosik AD, Coleman M, Kostakoglu L, Furman RR, Fiore JM, Muss D, Niesvizky R, Shore T, Schuster MW, Stewart P, Vallabhajosula S, Goldsmith SJ, Leonard JP.
Dosik AD, et al. Among authors: kostakoglu l.
Cancer. 2006 Feb 1;106(3):616-22. doi: 10.1002/cncr.21606.
Cancer. 2006.
PMID: 16362977
Free article.